
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

For the month of March 2024

Commission File Number: **001-39777**

Nanobiotix S.A.

(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

On March 6, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[\(c\) Exhibit 99.1. Press release dated March 6, 2024](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nanobiotix S.A.
(Registrant)

Date: March 6, 2024

/s/ Bart Van Rhijn
Bart Van Rhijn
Chief Financial Officer

Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBOTIX (Euronext: NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.

Leerink Partners Global Biopharma Conference

Date: Wednesday, March 13, 2024

Time: 8:40 AM EST / 1:40 PM CET

Location: Miami, FL

Presenter: Laurent Levy, co-founder of Nanobiotix and chairman of the executive board

Guggenheim Healthy Altitudes Summit

Date: Wednesday, March 13, 2024

Time: 8:15 AM MST / 4:15 PM CET

Location: Telluride, CO

Presenter: Bart Van Rhijn, chief financial officer of Nanobiotix

The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. Replays of the webcasts will be available following the events.

About NANOBOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Investor Relations Department

Craig West

SVP, Investor Relations

+1 (617) 583-0211

investors@nanobiotix.com

Media Relations

FR – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysses-communication.com

Global – LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

kgardner@lifesciadvisors.com

Attachment

- 2024-03-06 -- NBTX -- Presenting @ March Conferences -- FINAL (1).pdf (<https://ml.globenewswire.com/Resource/Download/b4318ecf-0daf-4ade-9046-14456bc8effb>)